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Abstract
Introduction: Since the U.S. Food and Drug Administration (FDA) was granted regulatory authority 
over tobacco products in 2009, few studies have examined perceived credibility of the FDA in this role. 
The current study assessed knowledge and credibility of the FDA as a regulator of tobacco products. 
Methods: In a nationally representative survey of U.S. adults (N = 4758), we assessed knowledge 
that the FDA regulates the manufacture, distribution, and marketing of cigarettes, and credibility of 
the FDA as a tobacco regulator. We examined demographic differences in knowledge and credibil-
ity, and associations of knowledge and trust in government with credibility perceptions. 
Results: Less than half of respondents reported knowing the FDA regulates how cigarettes are sold 
(46.8%) and advertised (49.7%), and only 36.0% knew the FDA regulates how cigarettes are made, 
with few demographic differences. Respondents reported that the FDA was moderately credible 
in regulating tobacco. Knowledge of the FDA as a tobacco regulator and trust in government were 
the strongest predictors of credibility. Being of younger age, being White (compared to African 
American), and being male were associated with higher credibility ratings of the FDA. 
Conclusions: Much of the public still does not know that the FDA regulates tobacco products, and 
credibility perceptions are moderate. Greater knowledge of the FDA’s regulatory role was associ-
ated with higher credibility; efforts that increase the public’s understanding of the FDA’s role as a 
tobacco regulator may positively impact views of the agency’s credibility. This may in turn improve 
public reception to the FDA’s messages and regulations.
Implications: This study is the first to show nationally representative estimates of both knowledge 
and credibility of the FDA as a tobacco regulator. Our research shows further that knowledge of the 
FDA’s tobacco regulatory roles is likely to be an important factor related to perceived credibility of 
the FDA. Increasing the public’s knowledge of the FDA’s roles may enhance the agency’s credibility, 
which can improve public reception to messages and regulations.
Introduction
The U.S. Food and Drug Administration (FDA) was given regulatory 
authority over cigarettes, roll your own tobacco products, and smoke-
less tobacco under the 2009 Family Smoking Prevention and Tobacco 
Control Act (FSPTCA), which mandates that the FDA oversee vari-
ous aspects of tobacco manufacturing, advertising, and sales.1 In May 
2016, the FDA issued a final “deeming” rule extending their regula-
tory authority from the limited tobacco products covered by FSPTCA 
to all tobacco products, including e-cigarettes, little cigars and cigaril-
los, and hookah.2 As a tobacco regulator, the FDA has broad authority 
to regulate the manufacture, distribution, and marketing of tobacco 
products, which includes developing and implementing public com-
munication campaigns about the harms of tobacco use, including The 
Real Cost,3 Fresh Empire,4 and This Free Life.5
Previous research has indicated that public knowledge of and 
beliefs about the credibility of an organization can impact the overall 
effectiveness of communication activities in changing attitudes and 
behavior6–8 and can enhance support for and compliance with rec-
ommendations and regulations.9–11 Source credibility itself is made 
up of two main underlying constructs: expertise, or the ability of an 
organization to know correct information, and trustworthiness, or 
the extent to which an organization presents what it believes to be 
correct information.6,7,12 Knowing that the FDA regulates the manu-
facturing, distribution (sales), and advertising of tobacco products, 
such as cigarettes, may inform views of the agency’s expertise in this 
role. For a government agency, the extent to which the agency is 
perceived to act in the public’s best interest is a third construct that 
is likely also to be a key element of credibility.6 One study about the 
FDA’s role in ensuring medication safety found that beliefs about 
the agency’s credibility (specifically trustworthiness in this case) can 
drive behavior change, as parents who trusted the FDA’s recommen-
dations about cold medications were more likely to follow these rec-
ommendations for their children.10 Another study tested the effect 
of source credibility on warnings for alcohol, cigarettes, and iron 
supplements, finding that the inclusion of a specific source (including 
the FDA) increased ratings of the credibility of the warning and com-
pliance intentions.11 Thus the public’s knowledge of the FDA’s roles 
as a tobacco regulator and beliefs about its credibility may impact 
the agency’s ability to successfully communicate with the public and 
implement new tobacco regulations.
Past research provides some insights into existing levels of know-
ledge about the FDA’s tobacco regulatory authority and its cred-
ibility, although several limitations remain to be addressed by the 
current research. With regard to knowledge, one study, conducted 
shortly after the FDA received authority to regulate tobacco prod-
ucts in 2009, found that most smokers did not know that the FDA 
had authority to regulate tobacco products.13 Another study, con-
ducted a few years later (2012–2013), showed that still less than half 
of the public knew that the FDA regulated tobacco products.14 Thus, 
even several years after the FDA gained regulatory authority over 
tobacco products, knowledge of this authority was not widespread. 
In another study, a majority (62.5%) of U.S. adults felt the FDA 
gave trustworthy information to the public, a related component 
to credibility.15 In a scale development study of the FDA’s tobacco-
related credibility, participants rated its credibility as moderately 
high, although this study used a convenience sample and was not 
nationally representative.16
The current study builds on this past research and is the first 
to report estimates of both knowledge and credibility of the FDA 
among a nationally representative sample of adults in the United 
States, specific to its tobacco regulatory role. In this study, we sought 
to understand the potential factors associated with public know-
ledge and credibility respectively. Additionally, based on our concep-
tualization of credibility as a construct made up of trustworthiness, 
expertise, and public interest, we hypothesized that having greater 
knowledge about the FDA as a regulator of tobacco products could 
enhance views of its credibility. We examined associations of demo-
graphic characteristics, behaviors, and beliefs with knowledge of the 
FDA as a regulator of tobacco products and perceived credibility of 
the FDA in this role.
Methods
A nationally representative telephone survey of adults aged 18 years 
or older was conducted between September 2014 and May 2015. 
Random digit dial (RDD) landlines and cell phone numbers that cov-
ered approximately 98% of the U.S. population were used. To over-
sample smokers, the poorest counties with the highest smoking rates 
were oversampled. Cell phones were oversampled to maximize inclu-
sion of young adults. Sampling weights were based on variables includ-
ing census region, age, education, gender, ethnicity, phone type (cell 
or landline), and regional smoking rates. The survey topics included 
tobacco communication, the FDA’s regulation of tobacco products, 
and chemicals in tobacco products. All newly developed survey meas-
ured were tested using cognitive interviewing, including the know-
ledge and credibility items used in the current study. The entire sample 
included 5014 interviews with a weighted response rate of 42%. 
Further details about the design and methods used in this national 
survey are provided in a separate paper.17 The study was approved by 
UNC Chapel Hill’s Institutional Review Board (#13–2779).
Outcome Measures
Knowledge of FDA Regulation of Tobacco
Survey respondents who answered “yes” to the question, “Have 
you ever heard of the FDA or the Food and Drug Administration?” 
received three additional questions in random order to assess their 
knowledge of the FDA’s regulation of tobacco products, with refer-
ence to cigarettes specifically, as cigarettes are the most commonly 
used and known tobacco product. The three questions were, “Do 
you think the FDA regulates how cigarettes are… (1) made, (2) sold 
in stores, (3) advertised?,” and participants were given “yes” and 
“no” as response options. If respondents did not answer “yes” or 
“no,” the interviewer coded their responses as “do not know” or 
“refused” as appropriate. “Yes” responses to each item were treated 
as separate outcomes in logistic regression models of knowledge. In 
linear regression models of credibility, “yes” responses to each know-
ledge item were coded as “1”, and summed to create a measure of 
knowledge that ranged from 0 to 3.
Credibility of FDA as a Tobacco Regulator
Prior to asking about perceived credibility of the FDA, the inter-
viewer informed all participants, “The FDA now regulates cigarettes 
and many other tobacco products. The next series of questions is 
about your opinions towards the FDA in this role.” Credibility was 
measured using eight items examining beliefs about the trustworthi-
ness, expertise, and public interest of the FDA as a tobacco regula-
tor.6 Items included, “Do you trust the FDA to inform the public 
about the risks of tobacco products?,” “Is the FDA honest about 
the risks of tobacco products?,” “Do you believe what the FDA says 
about the risks of tobacco products?,” “Is the FDA an expert on 
regulating tobacco products?,” “Is the FDA capable of doing a good 
job regulating tobacco products?,” “Can the FDA effectively regulate 
tobacco products?,” “Is the FDA committed to protecting the public 
from possible risks of tobacco products?,” and “Do you believe that 
if the FDA knew that certain tobacco products are less harmful than 
thought, they would tell the public?”. Respondents answered “yes” 
or “no” to each item. Interviewers coded other responses as “do not 
know” or “refused” as appropriate. “Yes” responses were summed 
to create a scale ranging from 0 to 8 with higher numbers indicative 
of higher perceived credibility. As a whole, this measure showed 
acceptable internal consistency (Cronbach’s α = 0.79).
Independent Variables
Demographic Characteristics
Demographic variables included age (grand mean centered), gender 
(male = 0, female = 1), race (Black/African American = 0, other race 
= 1, White = 2), ethnicity (Latino = 0, not Latino = 1), poverty status 
(income above = 0 or below = 1 the poverty line), sexual orientation 
(gay, lesbian, or bisexual [GLB] = 0 or not GLB = 1), education (less 
than high school = 5, high school diploma or general equivalency 
diploma = 4, some college = 3, associate’s degree = 2, college degree 
= 1, or graduate degree = 0) and current smoking status (current 
smokers were defined as having smoked at least 100 cigarettes in 
their lifetime and currently smoke some days or every day; current 
smoker = 0, not a current smoker = 1). We were most interested in 
current smoking status (rather than lifetime smoking status), as cur-
rent smokers would likely be the most directly impacted by the FDA’s 
regulation of tobacco products. Levels of each categorical variable 
with the highest numerical code were set as the reference groups.
Beliefs
Trust in the federal government was measured using the item “How 
much trust do you have in the Federal government?” Responses were 
coded as 0 = none at all, 1 = not very much, 2 = no opinion, 3 = a fair 
amount, 4 = a great deal; participants who reported “don’t know” or 
who refused to answer this question were coded as missing.
Analyses
Sample characteristics are given for the entire survey sample (N = 
5014). Descriptive analyses of knowledge and credibility percep-
tions, as well as regression analyses included respondents who 
reported that they had heard of the FDA (N = 4758, 94.9% of total 
sample). Cases with missing data on any covariates were dropped 
from their respective regression models. All analyses were performed 
in SAS 9.4 using the survey design features of the study. Weighted 
sample means and proportions with 95% confidence intervals were 
produced and surveylogistic and surveyregression procedures were 
used. In models with knowledge and credibility as the outcome, we 
tested factors that predicted “yes” responses to these items, or, in 
other words, greater knowledge and higher perceptions of credibil-
ity. We first conducted three logistic regression models to assess the 
relationships between demographic and belief variables and know-
ledge that the FDA regulates how tobacco products are made, sold, 
and advertised, respectively. Second, we used linear regression to 
assess the associations between demographic and belief variables 
and credibility of the FDA. We conducted two linear regression mod-
els, the first containing only the demographic variables and the sec-
ond which added the belief and knowledge variables.
Results
Sample Characteristics and Descriptive Analyses
Weighted sample characteristics are provided in Table 1 and are simi-
lar to U.S. population characteristics with regard to gender (48.5% 
male), race (67.9% White), Hispanic ethnicity (14.2%), education 
(42.6% with a high school diploma or less), poverty status (17.5% 
living below the poverty line), sexual orientation (96.8% heterosex-
ual), and current smoking (17.5% current smokers). Unweighted 
sample characteristics are also shown in this table for reference. 
Weighted data was used for all analyses.
Just over one-third of respondents knew that the FDA regulates 
how cigarettes are made (36.0%), while just less than half knew that 
the FDA regulates how cigarettes are advertised (49.7%), and sold in 
stores (46.8%). When evaluating the “yes” responses across all three 
domains, 26.3% of participants did not know the FDA regulated 
any of these three domains. Of the 73.7% that did know the FDA 
regulated at least one domain, 25.6% knew that the FDA regulated 
only one of these domains, 28.5% knew that the FDA regulated 
two of these domains, and 19.7% knew that the FDA regulated all 
three of these domains. The public viewed the FDA to be moderately 
credible on tobacco issues, shown by a mean response of 4.6 on a 
scale of 0 to 8. Weighted frequencies of responses to each of the 
credibility items are shown in Table 2. Several items showed simi-
lar degrees of endorsement; most were supported by over half to 
three-quarters of participants. The two items were supported by less 
than half of participants were, “Is the FDA an expert on regulating 
tobacco products?” and “Do you believe that if the FDA knew that 
certain tobacco products are less harmful than thought, they would 
tell the public?”
Knowledge of FDA as a Tobacco Regulator
Being male (compared to female) was associated with 1.28 higher 
odds of knowing the FDA regulates how cigarettes are made (see 
Table 3). There were no significant predictors of knowledge that the 
FDA regulates how cigarettes are sold. In the model of knowledge 
that the FDA regulates how cigarettes are advertised, those with a 
bachelor’s degree, compared to those with less than a high school 
education, had 1.70 higher odds of knowing that the FDA regulates 
how cigarettes are advertised, and current smokers, compared to 
nonsmokers, had 1.53 higher odds of knowing that the FDA regu-
lates how cigarettes are advertised.
Credibility of FDA
In the model assessing the relationships between demographic pre-
dictors and the credibility of the FDA (Model 1, Table 4), being of 
older age and a current smoker were associated with lower percep-
tions of the FDA’s credibility. Gender and education were also sig-
nificantly related to the FDA’s credibility; males and those with a 
graduate-level education (compared to a less than high school educa-
tion) had higher perceptions of the FDA’s credibility. The R2 was very 
low at 0.04, indicating that demographic characteristics explained 
little variance in perceptions of credibility.
In the next model, which included the above demographics 
and two belief variables, age, gender, race, knowledge of the FDA’s 
tobacco regulatory role, and trust in the federal government were 
all significantly associated with credibility perceptions (Model 2, 
Table  4). Being male (compared to female) was associated with 
higher perceptions of the FDA’s credibility, and each additional year 
of age and being African American (compared to White) were associ-
ated with lower perceptions of the FDA’s credibility. Greater know-
ledge of the FDA’s roles and trust in the federal government showed 
the largest positive association with higher credibility ratings. The R2 
of this model, though still low, was more than four times that of the 
previous model at 0.19, with the added contributions of knowledge 
of the FDA’s roles and trust in the Federal government.
Discussion
This is the first national study to examine both knowledge and cred-
ibility of the FDA as a tobacco regulator, as well as variables associ-
ated with both of these constructs. In the first six years since the 
passage of the 2009 FSPTCA, overall levels of knowledge about the 
FDA’s new regulatory role remain relatively low, although may show 
Table 2. Weighted Frequencies of Responses to FDA Credibility Questions
Credibility items % Yes (95% CI)
Do you trust the FDA to inform the public about the risks of tobacco products? 67.2 (64.8–69.6)
Is the FDA honest about the risks of tobacco products? 61.5 (59.0–64.1)
Do you believe what the FDA says about the risks of tobacco products? 74.6 (72.3–76.9)
Is the FDA an expert on regulating tobacco products? 33.4 (31.0–35.8)
Is the FDA capable of doing a good job regulating tobacco products? 61.1 (58.6–63.5)
Can the FDA effectively regulate tobacco products? 54.2 (51.7–56.8)
Is the FDA committed to protecting the public from possible risks of tobacco products? 55.7 (53.2–58.3)
Do you believe that if the FDA knew that certain tobacco products are less harmful than thought, 
they would tell the public?
43.7 (41.2–46.3)
CI = confidence interval; FDA = Food and Drug Administration.
Table 1. Weighted Sample Characteristics
Demographic characteristics Unweighted % or mean
Weighted % or 
mean 95% CI
Gender
 Male 47.3 48.5 46.0–51.0
 Female 52.7 51.5 49.0–54.0
Age, years 45.9 46.7 45.8–47.7
Race
 White 69.6 67.9 65.6–70.4
Black or African American 19.6 18.3 16.3–20.3
Other race 10.8 13.7 12.0–15.5
Ethnicity
 Latino/Hispanic 8.6 14.2 12.4–16.0
 Non-Latino/Hispanic 91.4 85.8 84.0–87.6
Education
<High School (HS) 10.5 11.2 9.2–13.2
G12 or GED, HS Diploma 24.7 31.4 28.8–34.0
Some college 20.7 20.7 18.8–22.6
Associate’s degree 9.9 10.5 9.0–12.0
Bachelor’s degree 21.2 15.7 14.3–17.1
Graduate or professional degree 13.0 10.5 9.4–11.6
Poverty status
Below poverty line 18.7 17.5 15.3–19.6
 Above poverty line 81.3 82.5 80.4–84.7
Sexual Orientation
Straight or heterosexual 96.1 96.8 96.1–97.4
Gay, lesbian, or bisexual 3.9 3.2 2.6–3.9
Current Cigarette Smoking
Current smoker 23.0 17.8 16.0–19.6
 Nonsmoker 77.0 82.2 80.4–84.0
Trust in the federal government (range: 0–4) 2.9 2.0 1.9–2.0
Knowledge that FDA regulates how cigarettes are…
Made? (% yes) 38.1 36.0 33.5–38.5
Sold in stores (% yes) 49.9 46.8 44.2–49.4
Advertised (% yes) 53.6 49.7 47.1–52.3
Credibility (range: 0 to 8; higher numbers indicative of 
higher credibility)
4.6 4.6 4.5–5.7
CI = confidence interval; FDA = Food and Drug Administration; GED = general equivalency diploma; GLB = gay, lesbian, or bisexual.
some signs of improvement.14 Specifically, while most of the sample 
did not know that the FDA regulates how cigarettes are made, sold, 
or advertised, when considered as separate outcomes, the majority 
of the sample did know that the FDA regulated at least one of those 
areas (74%). Despite these gaps in knowledge, U.S. adults believe 
that the FDA is moderately credible when it comes to regulating 
tobacco products. These results have implications for policy mak-
ers and organizations interested in strengthening the FDA’s tobacco-
related efforts.
In our knowledge models, many demographic and smoking sta-
tus variables were not significantly associated with knowing that the 
FDA regulates tobacco products. This result is promising because 
we did not observe large disparities in knowledge across people of 
different genders, races, ethnicities, poverty statuses, smoking sta-
tuses, sexual orientations, or levels of education. These results stand 
somewhat in contrast to an earlier study that found knowledge of 
the FDA’s tobacco regulatory role differed by some demographic 
groups, such that males, older participants, and those with lower 
Table 3. Factors Associated with the Odds of Knowing that the FDA Regulates How Cigarettes are Made, Sold, and Advertised
Made Sold Advertised
OR (95% CI) OR (95% CI) OR (95% CI)
Male 1.28 (1.01, 1.61)* 1.16 (0.93, 1.45) 1.19 (0.96, 1.48)
Age 0.99 (0.98, 1.00) 0.99 (0.98, 1.00) 1.00 (0.99, 1.01)
Latino 0.87 (0.60, 1.28) 0.84 (0.58, 1.20) 0.75 (0.52, 1.08)
Race
Black or African American 0.96 (0.71, 1.32) 0.96 (0.71, 1.30) 0.80 (0.60, 1.06)
 Other Race 0.80 (0.55, 1.16) 1.02 (0.72, 1.45) 1.07 (0.75, 1.51)
Education
Graduate or professional degree 1.20 (0.69, 2.08) 1.67 (0.98, 2.85) 1.38 (0.81, 2.37)
Bachelor’s degree 1.10 (0.65, 1.86) 1.48 (0.89, 2.47) 1.70 (1.01, 2.85)*
Associate’s degree 0.91 (0.51, 1.63) 1.24 (0.71, 2.16) 1.24 (0.70, 2.17)
Some college, no degree 1.06 (0.63, 1.78) 1.32 (0.80, 2.18) 1.65 (1.00, 2.73)
HS diploma or GED 0.98 (0.57, 1.68) 1.24 (0.74, 2.08) 1.35 (0.81, 2.27)
Poverty status 1.24 (0.86, 1.80) 1.27 (0.96, 1.67) 0.90 (0.64, 1.27)
GLB 0.76 (0.47, 1.21) 1.09 (0.69, 1.72) 1.19 (0.73, 1.93)
Current smoker 1.14 (0.85, 1.52) 1.27 (0.96, 1.67) 1.53 (1.16, 2.03)*
Referent groups are Female, not Latino, White, less than high school education, income above poverty line, not GLB, not a current smoker.
CI = confidence interval; FDA = Food and Drug Administration; GED = general equivalency diploma; GLB = gay, lesbian, or bisexual; OR = odds ratio.
*95% CI does not include 1.
Table 4. Factors Associated With FDA Credibility
Model 1: Demographics Model 2: Demographics and beliefs
β (SE) p β (SE) p
Intercept 0.00 (0.32)** <.0001 0.00 (0.32)** <.0001
Age −0.13 (0.00)** <.0001 −0.11 (0.00)** <.0001
Male 0.07 (0.12)* .01 0.05 (0.11)* .04
Latino −0.03 (0.20) .35 −0.04 (0.20) .18
Race
African American/Black −0.03 (0.16) .30 −0.06 (0.14)* .01
 Other race −0.02 (0.18) .55 −0.04 (0.17) .11
Below poverty line 0.02 (0.21) .54 0.00 (0.17) .88
Smoker −0.06 (0.16)* .03 −0.04 (0.14) .10
GLB 0.01 (0.23) .54 0.00 (0.21) .80
Education
Graduate degree 0.10* (0.33) .03 0.05 (0.30) .25
Bachelor’s degree 0.02 (0.31) .67 −0.01 (0.29) .83
Associate’s degree −0.01 (0.33) .83 −0.02 (0.30) .64
Some college −0.04 (0.31) .50 −0.05 (0.28) .29
HS diploma or GED −0.04 (0.31) .54 −0.06 (0.28) .33
FDA knowledge (range: 0 to 3) 0.24 (0.06)** <.0001
Trust in federal government 0.30 (0.05)** <.0001
Variance explained: R2 0.04 0.19
Referent groups are Female, not Latino, White, less than high school education, income above poverty line, not GLB, not a current smoker.
β reflects standardized estimates.
FDA = Food and Drug Administration; GED = general equivalency diploma; GLB = gay, lesbian, or bisexual; HS = high school.
*p < .05.
**p < .0001.
education were more likely to believe that their current brand of 
cigarette had been evaluated by the government.13 It may be that as 
time since the passage of the FSPTCA elapses, disparities in know-
ledge across demographic factors are closing, perhaps due to visibil-
ity of the FDA’s media campaigns (such as the The Real Cost),3 news 
media coverage of the FDA’s actions (such as of challenges to graphic 
warning label regulations18 and new regulations on e-cigarettes19), or 
policy enforcement. To fully understand these results, future research 
should examine overall levels of knowledge of the FDA’s regulation 
of tobacco products and differences in knowledge by demographic 
groups that arise over time; understanding such disparities in know-
ledge may be important to closing disparities in tobacco use as a 
whole.20,21
Our models of credibility showed that regardless of ethni-
city, smoking status, sexual orientation, and poverty status (above 
or below the poverty line), ratings of credibility of the FDA were 
largely similar. In our study, overall levels of credibility were moder-
ate, which demonstrated that the public perceives the FDA as gen-
erally competent in its tobacco regulatory role. In an age of historic 
lows in trust of the federal government,22 these results are encourag-
ing. More importantly perhaps, factors with the greatest associations 
with credibility were level of knowledge about the FDA’s tobacco 
regulatory role and general trust in the Federal government. These 
knowledge and belief variables showed effects after controlling for 
demographic characteristics, and, when added to the model, even 
removed the effect of smoking status on credibility. As the number 
of tobacco regulatory roles that a participant knew about increased, 
their ratings of the credibility of the FDA also increased, suggesting 
that increasing the public’s awareness of the FDA’s regulatory roles 
over tobacco marketing, sales, and advertising may positively impact 
perceptions of the FDA’s credibility. The more that the public learns 
that the FDA regulates tobacco, the more they may trust the FDA 
and view the FDA to be expert in this role.
Although overall assessment of the FDA’s credibility was moder-
ate, two of the eight items in this credibility scale, which pertained 
to expertise and public interest, received affirmative responses from 
less than half of the sample, suggesting specific areas where the 
FDA’s credibility can be increased. These items included whether 
the FDA is an expert at regulating tobacco, and whether the agency 
would tell the public if it knew that certain tobacco products were 
less harmful than originally thought. The first of these two items 
may result from a lack of knowledge of the FDA’s regulatory roles, 
shown by responses to our knowledge items as well; if less than 
half of respondents knew that the FDA regulated each domain of 
tobacco product manufacturing, advertising, and sales, many may 
not perceive the FDA to be an expert in this role. By educating the 
public about its regulatory role and evidence-based process of pol-
icymaking, the FDA may be able to increase views about its expertise 
in this area. Such impact may come about as the FDA takes more 
actions that reach large proportions of the public, such as nation-
wide implementation of pictorial warnings on cigarette packs, which 
has been stalled due to industry litigation.23 Additionally, increasing 
transparency of regulatory action, and highlighting ways that the 
public can provide feedback about tobacco regulation may further 
enhance views that the agency is working in the public interest, and 
also increase ratings of credibility.
Future research should explore any potential unintended conse-
quences of enhancing knowledge of and beliefs about the credibility 
of the FDA as a tobacco regulator, particularly if those who know 
the FDA regulates tobacco and believe the agency to be credible in 
this role inadvertently believe that tobacco products are safer now 
that they are regulated. In a study on dietary supplements, inform-
ing participants that the FDA did not approve a supplement low-
ered ratings of safety, suggesting such an effect.24 Traditionally, the 
FDA’s role with regard to food and medications has been to ensure 
safety, making the role of regulating tobacco unusual because 
tobacco inherently causes harm. Products such as e-cigarettes may 
also be perceived differently now that the FDA has gained regula-
tory authority over them.2 In a study of smokers conducted in 2001, 
those who believed the FDA did not evaluate cigarettes for safety 
showed greater understanding of the health risks of smoking and 
were more likely to report quit intentions, suggesting that beliefs 
about the FDA’s regulatory authority could be tied to beliefs about 
tobacco product risks and quit intentions.25 On the other hand, one 
national study indicates 43% of smokers report that they would per-
ceive tobacco to be more harmful if tobacco products were regu-
lated by the government.13 Therefore, knowing tobacco is regulated 
by the FDA, a government agency, may actually have the opposite 
effect (ie, lead to perceptions that tobacco products are more harm-
ful), although this should be examined in future research. The FDA’s 
communication campaigns about the harms of tobacco should help 
guard against perceptions that tobacco products are safe,3–5 and 
make known that the FDA is committed to protecting the public 
from these risks.
Another area for future research is to understand more about 
individuals who report uncertainty in knowledge and perceived 
credibility of the FDA. In studies asking participants to assess their 
health risks, “don’t know” responses have been linked to variables 
associated with vulnerable populations, such as low education.26 
Understanding the characteristics and beliefs of individuals who 
report uncertainty may have important implications for behavior. 
In past research on regulation by the FDA, not knowing whether 
the FDA regulated tobacco products was associated with uncer-
tainty about the harms of different types of tobacco products.14 
While the aim of the current paper was to test factors associated 
with higher knowledge and credibility perceptions (ie, affirmative 
“yes” responses to our survey items), knowing more about those 
who express uncertainty about these constructs may be useful for 
planning communication and regulatory efforts.
Limitations
There are some limitations of this work. We asked specifically about 
cigarettes (rather than tobacco products in general) in the regula-
tory knowledge questions, as it is the most familiar of all tobacco 
products. It may be that even fewer people than reported in this 
study knew that the FDA regulates other forms of tobacco products. 
One element of the FDA’s role as a tobacco regulator that was not 
included in our credibility measure is the FDA’s enforcement role;27 
credibility items about the agency’s expertise and trustworthiness 
as a law enforcement body should be explored in future research.
Conclusions
This study is the first to show national estimates of both know-
ledge and credibility of the FDA as a tobacco regulator and factors 
associated with each. Tangible methods exist to increase the public’s 
understanding of the FDA’s roles, and knowledge is likely to be an 
important factor related to the credibility of the FDA. Demonstrating 
the FDA’s expertise in tobacco regulation and promoting transpar-
ency in its regulatory processes are likely to further enhance its 
credibility, and potentially public responsiveness to the FDA’s com-
munication campaigns and regulatory actions.
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